Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04404283 | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | PHASE3 | ACTIVE NOT_RECRUITING | 239 | — | — | Aug 20, 2020 | Dec 31, 2026 | Apr 20, 2026 | 145 | United States, Australia +12 |
OS is defined as the time from the date of randomization to date of death due to any cause
| Arm | Type | Description |
|---|---|---|
| Experimental Arm | EXPERIMENTAL | Brentuximab vedotin + lenalidomide + rituximab |
| Control Arm | ACTIVE_COMPARATOR | Placebo + lenalidomide + rituximab |
| Name | Type | Description |
|---|---|---|
| Brentuximab vedotin | DRUG | 1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks |
| Rituximab | DRUG | 375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment. |
| Lenalidomide | DRUG | 20 mg given by mouth (orally) daily |
| Placebo | OTHER | Administered via intravenous infusion every 3 weeks |
Inclusion Criteria: * Participants with relapsed or refractory diffuse and transformed large B-cell lymphoma (R/R DLBCL). DLBCL and cell of origin (GCB versus non-GCB) will be histologically determined by local pathology assessment for the purposes of study eligibility and stratification. * Partici...